Results 141 to 150 of about 26,895 (263)

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Clinical Interpretation of Modest Blood Pressure Changes After SGLT2 Inhibitor Initiation. [PDF]

J Clin Hypertens (Greenwich)
Şahin MA, Karaarslan O, Yılmaz MM, Kalçık M.   +3 more
europepmc   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Association Between SGLT2 Inhibitor Use and Hepatocellular Carcinoma Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis. [PDF]

Biomedicines
Hu JH, Chang ML, Huang TJ, Liu NJ, Tang JH.   +4 more
europepmc   +1 more source

SGLT2 inhibitors: the story continues to unfold [PDF]

European Heart Journal, 2021
openaire   +2 more sources

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study. [PDF]

Clin Kidney J
Chen YT, Wang CA, Chen JY, Wu VC.
europepmc   +1 more source

Pre‐Exercise Galactose or Lactose Reduces Glycaemic Excursions During Exercise in Adults With Type 1 Diabetes: A Randomised, Double‐Blind, Crossover Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To test whether pre‐exercise galactose and lactose reduce glycaemic excursions during exercise compared with dextrose while maintaining protection against hypoglycaemia compared with placebo in adults with Type 1 diabetes Methods In a randomised, double‐blind, 4‐condition crossover trial, 14 adults with Type 1 diabetes completed four 60 ...
Karoline R. Schmidt, Rakel F. Johansen, Simon B. Riis, Mads S. Larsen, Henrik Støvring, Gareth A. Wallis, David Rowlands, Lars C. Gormsen, Esben Søndergaard   +8 more
wiley   +1 more source

Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use. [PDF]

J Korean Med Sci
Bae S, Yun D, Kim J, Park S, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, Han SS.   +9 more
europepmc   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale, K. G. Young, P. Cardoso, L. M. Güdemann, T. T. Jansz, A. P. McGovern, A. G. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. M. Shields, J. M. Dennis   +11 more
wiley   +1 more source